Terms: = Ovarian cancer AND ABL2, ARG, 27, ENSG00000143322, P42684, ABLL, RP11-177A2_3 AND Clinical Outcome
403 results:
1. Machine learning developed a fibroblast-related signature for predicting clinical outcome and drug sensitivity in ovarian cancer.
Fu W; Feng Q; Tao R
Medicine (Baltimore); 2024 Apr; 103(16):e37783. PubMed ID: 38640321
[TBL] [Abstract] [Full Text] [Related]
2. Machine learning developed a CD8
Chen R; Zheng Y; Fei C; Ye J; Fei H
Sci Rep; 2024 Mar; 14(1):5794. PubMed ID: 38461331
[TBL] [Abstract] [Full Text] [Related]
3. Developing a novel image marker to predict the clinical outcome of neoadjuvant chemotherapy (NACT) for ovarian cancer patients.
Zhang K; Abdoli N; Gilley P; Sadri Y; Chen X; Thai TC; Dockery L; Moore K; Mannel RS; Qiu Y
Comput Biol Med; 2024 Apr; 172():108240. PubMed ID: 38460312
[TBL] [Abstract] [Full Text] [Related]
4. Tumor-Stroma Proportion to Predict Chemoresistance in Patients With ovarian cancer.
Lou E; Clemente V; Grube M; Svedbom A; Nelson AC; Blome F; Staebler A; Kommoss S; Bazzaro M
JAMA Netw Open; 2024 Feb; 7(2):e240407. PubMed ID: 38411963
[TBL] [Abstract] [Full Text] [Related]
5. Vdelta1 T cells are more resistant than Vdelta2 T cells to the immunosuppressive properties of galectin-3.
Schadeck J; Oberg HH; Peipp M; Hedemann N; Schamel WW; Bauerschlag D; Wesch D
Front Immunol; 2023; 14():1286097. PubMed ID: 38259448
[TBL] [Abstract] [Full Text] [Related]
6. Long Non-Coding RNAs: Bridging cancer-Associated Thrombosis and clinical outcome of ovarian cancer Patients.
Marques IS; Tavares V; Savva-Bordalo J; Rei M; Liz-Pimenta J; de Melo IG; Assis J; Pereira D; Medeiros R
Int J Mol Sci; 2023 Dec; 25(1):. PubMed ID: 38203310
[TBL] [Abstract] [Full Text] [Related]
7. HRD related signature 3 predicts clinical outcome in advanced tubo-ovarian high-grade serous carcinoma.
Koskela H; Li Y; Joutsiniemi T; Muranen T; Isoviita VM; Huhtinen K; Micoli G; Lavikka K; Marchi G; Hietanen S; Virtanen A; Hautaniemi S; Oikkonen J; Hynninen J
Gynecol Oncol; 2024 Jan; 180():91-98. PubMed ID: 38061276
[TBL] [Abstract] [Full Text] [Related]
8. Timed adoptive T cell transfer during chemotherapy in patients with recurrent platinum-sensitive epithelial ovarian cancer.
Verdegaal EME; Santegoets SJ; Welters MJP; de Bruin L; Visser M; van der Minne CE; de Kok PM; Loof NM; Boekestijn S; Roozen I; Westra IM; Meij P; Van der Burg SH; Kroep JR
J Immunother Cancer; 2023 Nov; 11(11):. PubMed ID: 37949617
[TBL] [Abstract] [Full Text] [Related]
9. Role of gene sequencing in classifying struma ovarii: BRAF p.G469A mutation and TERT promoter alterations favour malignant struma ovarii.
Neyrand S; Trecourt A; Lopez J; Just PA; Descotes F; Borson-Chazot F; Ray-Coquard I; Decaussin-Petrucci M; Devouassoux-Shisheboran M
Histopathology; 2024 Jan; 84(2):291-300. PubMed ID: 37771077
[TBL] [Abstract] [Full Text] [Related]
10. Percutaneous nephrostomy catheter-related infections in patients with gynaecological cancers: a multidisciplinary algorithmic approach.
Szvalb AD; Marten C; Cain K; Taylor JS; Huang SY; Jiang Y; Raad II; Viola GM
J Hosp Infect; 2023 Nov; 141():99-106. PubMed ID: 37696471
[TBL] [Abstract] [Full Text] [Related]
11. clinical outcome and Morphology-Based Analysis of p53 Aberrant and Mismatch Repair Protein-Deficient ovarian Clear Cell Carcinoma and Their Association With p16, HER2, and PD-L1 Expression.
Wilkins R; Lin LH; Xia R; Shiomi T; Zamuco RD; Shukla PS
Am J Clin Pathol; 2023 Nov; 160(5):466-476. PubMed ID: 37415414
[TBL] [Abstract] [Full Text] [Related]
12. FOXL2 Mutation Status in Sex Cord-stromal Tumors Cannot be Predicted by Morphology.
Wessman S; Fuentes BB; Severin-Karlsson J; Westbom-Fremer S; Nistér M; Kokaraki G; Petta TB; Haglund F; Carlson JW
Int J Gynecol Pathol; 2024 Jan; 43(1):78-89. PubMed ID: 37255476
[TBL] [Abstract] [Full Text] [Related]
13. Whole exome sequencing of low grade serous ovarian carcinoma identifies genomic events associated with clinical outcome.
Thomson JP; Hollis RL; van Baal J; Ilenkovan N; Churchman M; van de Vijver K; Dijk F; Meynert AM; Bartos C; Rye T; Croy I; Diana P; van Gent M; Creedon H; Nirsimloo R; Nussey F; Lok C; Herrington CS; Gourley C
Gynecol Oncol; 2023 Jul; 174():157-166. PubMed ID: 37207500
[TBL] [Abstract] [Full Text] [Related]
14. Low plasma PD-L1 levels, early tumor onset and absence of peritoneal carcinomatosis improve prognosis of women with advanced high-grade serous ovarian cancer.
Fanale D; Brando C; Corsini LR; Cutaia S; Di Donna MC; Randazzo U; Filorizzo C; Lisanti C; Magrin L; Gurrera V; Romano R; Dimino A; Bazan Russo TD; Olive D; Vieni S; Pantuso G; Giordano A; Chiantera V; Russo A; Bazan V; Iovanna JL
BMC Cancer; 2023 May; 23(1):437. PubMed ID: 37179293
[TBL] [Abstract] [Full Text] [Related]
15. Targeting homologous recombination deficiency in uterine leiomyosarcoma.
Dall G; Vandenberg CJ; Nesic K; Ratnayake G; Zhu W; Vissers JHA; Bedő J; Penington J; Wakefield MJ; Kee D; Carmagnac A; Lim R; Shield-Artin K; Milesi B; Lobley A; Kyran EL; O'Grady E; Tram J; Zhou W; Nugawela D; Stewart KP; Caldwell R; Papadopoulos L; Ng AP; Dobrovic A; Fox SB; McNally O; Power JD; Meniawy T; Tan TH; Collins IM; Klein O; Barnett S; Olesen I; Hamilton A; Hofmann O; Grimmond S; Papenfuss AT; Scott CL; Barker HE
J Exp Clin Cancer Res; 2023 May; 42(1):112. PubMed ID: 37143137
[TBL] [Abstract] [Full Text] [Related]
16. An angiogenic tumor phenotype predicts poor prognosis in ovarian cancer.
Wieser V; Tsibulak I; Reimer DU; Zeimet AG; Fiegl H; Hackl H; Marth C
Gynecol Oncol; 2023 Mar; 170():290-299. PubMed ID: 36758419
[TBL] [Abstract] [Full Text] [Related]
17. Isolated lymph node recurrence in epithelial ovarian cancer - management and outcome.
Jain V; Debnath S; Sharma A; Kamboj M; Mohanty A; Rawal S
J Visc Surg; 2023 Jun; 160(3):169-179. PubMed ID: 36564260
[TBL] [Abstract] [Full Text] [Related]
18. Discovery of pathway-independent protein signatures associated with clinical outcome in human cancer cohorts.
Konaté MM; Li MC; McShane LM; Zhao Y
Sci Rep; 2022 Nov; 12(1):19283. PubMed ID: 36369472
[TBL] [Abstract] [Full Text] [Related]
19. Immunohistochemical evaluation of forkhead box A1 and EphA5 markers in serous ovarian carcinomas, and their impact on the clinical outcome of patients.
Abouhashem N; Harb O; Elwan A; Zaitoun M; Saraya Y
Pol J Pathol; 2022; 73(2):120-133. PubMed ID: 36345952
[TBL] [Abstract] [Full Text] [Related]
20. Expression of epithelial-mesenchymal transition biomarkers: Discoidin domain receptor 2, Snail-1, and Ovol-2 as predictors of clinical outcome in patients with epithelial ovarian carcinoma.
Harb OA; Elfeky MA; El-Beshbishi W; Obaya AA; Abdallah WM; Ibrahim A; Awd AA; Embaby A
J Cancer Res Ther; 2022; 18(4):1073-1082. PubMed ID: 36149163
[TBL] [Abstract] [Full Text] [Related]
[Next]